Welcome to our dedicated page for Matinas BioPharma Holdings news (Ticker: MTNB), a resource for investors and traders seeking the latest updates and insights on Matinas BioPharma Holdings stock.
Matinas BioPharma Holdings, Inc. (NYSE: MTNB) is a clinical-stage biopharmaceutical company dedicated to advancing innovative anti-infective therapies for orphan indications. Utilizing proprietary lipid-crystal nano-particle cochleate technology, Matinas BioPharma aims to enhance the safety, tolerability, and oral bioavailability of existing drugs, thereby reducing their toxicity and improving patient outcomes.
The company's leading drug candidate, MAT2203, is an orally-administered, encochleated formulation of amphotericin B, a broad-spectrum fungicidal agent. Currently in Phase 2 clinical trials, MAT2203 seeks to offer a less toxic and more effective oral treatment for severe fungal infections.
Another promising candidate is MAT2501, an orally-administered, encochleated formulation of amikacin. Amikacin is a broad-spectrum aminoglycoside antibiotic agent effective against acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram-negative bacterial infections. MAT2501 is currently in Phase 1 clinical trials, following an open Investigational New Drug (IND) application.
Matinas BioPharma's innovative approach positions the company at the forefront of developing next-generation anti-infective therapies. The firm's pipeline also includes other drug candidates that aim to address unmet medical needs in infectious disease treatment. By leveraging its nano-encapsulation technology, Matinas BioPharma is committed to creating safer and more effective treatments for patients.
Latest News:
- A photo accompanying this announcement is available
- Studies in neutropenic mouse model demonstrate prolonged and enhanced survival, reduced fungal burden, and improvement in lung infection.
- Investor Contact: LHA Investor Relations, Jody Cain, Jcain@lhai.com, 310-691-7100
Matinas BioPharma Holdings, Inc. (MTNB) reports Q1 2021 results with significant progress in clinical studies. Patient enrollment in the EnACT study for MAT2203, targeting cryptococcal meningitis, is at 70%, with a DSMB evaluation expected in Q3 2021. MAT2501 advances to preclinical studies, aiming for a Phase 1 study by year-end. Financially, cash reserves stand at $60.7 million, aiding operations into 2024. A net loss of $5.2 million was reported, unchanged from Q1 2020, while R&D expenses decreased to $3.2 million. Management remains optimistic about future developments and partnerships.
Matinas BioPharma (MTNB) announced that CEO Jerome D. Jabbour will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on May 5, 2021, at 11:20 a.m. ET. The company will also host investor meetings during the event. A live webcast of the presentation will be available on the company's website, with a replay accessible for 90 days. Matinas focuses on improving drug delivery through its lipid nanocrystal (LNC) platform and is developing multiple product candidates, including MAT2203 and MAT2501 for serious infections.
Matinas BioPharma Holdings (MTNB) will host a conference call on May 10, 2021, at 8:00 a.m. ET to discuss its Q1 2021 operational and financial results. The call can be accessed by dialing (877) 407-5976 (Toll-Free) or (412) 902-0031 (Toll), and will also be available via live webcast on the company's website. Matinas focuses on lipid nanocrystal technology for drug delivery, with ongoing studies for MAT2203, MAT2501, and LYPDISO, aimed at treating serious infections and cardiovascular conditions. Investors should note the inherent risks and uncertainties in their forward-looking statements.
Matinas BioPharma Holdings (MTNB) announced that CEO Jerome D. Jabbour will present an overview of the company at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 4:30 p.m. ET. The presentation will be available via live webcast on the company's investor relations page, with a replay accessible for 90 days. Matinas is focused on its innovative lipid nanocrystal delivery platform, developing products like MAT2203 for fungal infections and MAT2501 for bacterial infections, both in advanced clinical stages.
Matinas BioPharma Holdings (MTNB) reported its Q4 and full-year 2020 financial results, showing a net loss of $6.6 million for Q4 and a total of $23.2 million for the year, reflecting increased R&D expenses. The company is focused on its Lipid Nanocrystal (LNC) platform for intracellular drug delivery, with ongoing enrollment in the EnACT study of MAT2203 for cryptococcal meningitis. Significant partnerships are in progress, including collaboration with NIAID on remdesivir. Cash reserves stand at $58.7 million, expected to fund operations into 2024.
Matinas BioPharma (NYSE: MTNB) announced a conference call on March 29, 2021, at 8:00 a.m. ET, to discuss its Q4 and full-year 2020 financial results. The call can be accessed by dialing (877) 407-5976 (Toll-Free) or (412) 902-0031 (Toll). Matinas is focused on developing therapeutics for unmet medical needs, including LYPDISO for hypertriglyceridemia and MAT2203 for cryptococcal meningitis in HIV patients. The company aims to solve drug delivery challenges through its proprietary lipid nanocrystal platform and has received funding from the Cystic Fibrosis Foundation to support MAT2501.
Matinas BioPharma (MTNB) announced CEO Jerome D. Jabbour will present a company overview at the Barclays Global Healthcare Conference on March 9, 2021, at 4:45 p.m. ET. The presentation will include investor meetings and will be available via a live webcast on the company’s investor relations page. Matinas focuses on developing innovative therapeutics, including LYPDISO for hypertriglyceridemia, MAT2203 for fungal infections, and MAT2501 for bacterial infections. The company aims to improve drug delivery through its proprietary lipid nanocrystal platform.
Matinas BioPharma Holdings announced the topline results for its ENHANCE-IT study, comparing LYPDISO™ against Vascepa®. Key findings showed a 46% relative increase in EPA levels and a 39% reduction in triglycerides (TGs) versus Vascepa, although the latter did not meet statistical significance. However, LYPDISO™ demonstrated significant reductions in several lipid and inflammatory markers in the per-protocol population. The study involved 100 participants and aimed to assess cardiovascular risk reduction potential.
Matinas BioPharma (NYSE: MTNB) announces CEO Jerome D. Jabbour will present a company overview at the ICR Conference 2021 on January 14, 2021, at 1:00 p.m. ET. He will also host virtual investor meetings. Investors can access a live webcast on the Company’s IR Calendar page, with a replay available for 90 days post-event. Matinas focuses on developing innovative therapeutics, including LYPDISO™, which targets hypertriglyceridemia, and MAT2203, an antifungal treatment currently in clinical trials. The Company’s technology aims to improve drug delivery and efficacy.
Matinas BioPharma Holdings (MTNB) announced that the FDA has conditionally accepted LYPDISO as the proposed brand name for its drug MAT9001, targeting cardiovascular and metabolic conditions. Additionally, the USPTO granted a Notice of Allowance for the trademark registration of LYPDISO. The company is preparing to submit a New Drug Application and expects topline data from its head-to-head study against Vascepa® in Q1 2021, with Phase 3 trials starting in H2 2021. These developments are significant for the potential commercialization of MAT9001.
FAQ
What is the current stock price of Matinas BioPharma Holdings (MTNB)?
What is the market cap of Matinas BioPharma Holdings (MTNB)?
What is Matinas BioPharma Holdings, Inc.?
What is MAT2203?
What is MAT2501?
What technology does Matinas BioPharma use?
What are the benefits of MAT2203?
What types of infections does MAT2501 target?
What is unique about Matinas BioPharma's approach?
Who can I contact for investor relations inquiries?
What is the status of MAT2203 clinical trials?
What recent achievements has Matinas BioPharma reported?
